Kangtai Biological: Shareholding ratio of shareholder Bo Pu private equity fund products decreased to 1.79%

Kangtai Biotech announced that on March 16, 2026, the shareholder Bopu private equity fund product transferred 9.215 million shares of the company it held through block trading to Huabao Wanying private equity fund product. The shareholding ratio of Bopu private equity fund product decreased from 2.61% to 1.79%, and the change in shareholding ratio touched a multiple of 1%. The shareholding ratio of the acquirer, Huabao Wanying private equity fund product, increased from 0.00% to 0.83%.